KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Xenon Pharmaceuticals (XENE) Shares Outstanding (2016 - 2025)

Historic Shares Outstanding for Xenon Pharmaceuticals (XENE) over the last 13 years, with Q3 2025 value amounting to $77.1 million.

  • Xenon Pharmaceuticals' Shares Outstanding rose 174.92% to $77.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77.1 million, marking a year-over-year increase of 174.92%. This contributed to the annual value of $76.4 million for FY2024, which is 138.66% up from last year.
  • Per Xenon Pharmaceuticals' latest filing, its Shares Outstanding stood at $77.1 million for Q3 2025, which was up 174.92% from $76.9 million recorded in Q2 2025.
  • Over the past 5 years, Xenon Pharmaceuticals' Shares Outstanding peaked at $77.1 million during Q3 2025, and registered a low of $41.0 million during Q1 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' median Shares Outstanding value was $63.7 million (recorded in 2023), while the average stood at $64.0 million.
  • Its Shares Outstanding has fluctuated over the past 5 years, first skyrocketed by 5137.78% in 2022, then skyrocketed by 138.66% in 2024.
  • Quarter analysis of 5 years shows Xenon Pharmaceuticals' Shares Outstanding stood at $51.6 million in 2021, then grew by 21.21% to $62.6 million in 2022, then grew by 20.42% to $75.4 million in 2023, then grew by 1.39% to $76.4 million in 2024, then rose by 0.92% to $77.1 million in 2025.
  • Its last three reported values are $77.1 million in Q3 2025, $76.9 million for Q2 2025, and $76.6 million during Q1 2025.